A Phase 1 Study of Reovirus Serotype 3 - Dearing Strain (REOLYSIN) (NSC 729968) in Patients With Ovarian, Primary Peritoneal and Fallopian Tube Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 09 Aug 2016
At a glance
- Drugs Pelareorep (Primary) ; Pelareorep (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 05 Aug 2016 Status changed from active, no longer recruiting to completed.
- 18 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.